Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08065010 · 1 trial · 1 indication
Part A
Part A
Part A
Part A
Part A
| Arm | Type | Description |
|---|---|---|
| Part A: Cohort 3: single ascending dose (SAD) | EXPERIMENTAL | Dose C - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 8: single ascending dose (SAD) | EXPERIMENTAL | Optional Japanese Cohort dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 1: single ascending dose (SAD) | EXPERIMENTAL | Dose A - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 5: single ascending dose (SAD) | EXPERIMENTAL | Dose E - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 7: single ascending dose (SAD) | EXPERIMENTAL | Dose G - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 4: single ascending dose (SAD) | EXPERIMENTAL | Dose D - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 2: single ascending dose (SAD) | EXPERIMENTAL | Dose B - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 9: single ascending dose (SAD) | EXPERIMENTAL | Optional Chinese Cohort dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 6: single ascending dose (SAD) | EXPERIMENTAL | Dose F - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 10: single ascending dose (SAD) | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part A: Cohort 11: single ascending dose (SAD) | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part B: Cohort 12: multiple dose | EXPERIMENTAL | Dose F - Participants will receive PF-08065010 or placebo. |
| Part B: Cohort 13: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Part B: Cohort 14: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo. |
| Name | Type | Description |
|---|---|---|
| PF-08065010 | DRUG | Experimental Pfizer compound which will be subcutaneous (SC) or intravenous (IV). |
| Placebo | DRUG | Placebo which will be SC or IV |
Inclusion Criteria: * male or female between 18 and 65 years of age * deemed to be healthy Exclusion Criteria: 1. Evidence or history of clinically significant medical conditions. 2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, he...
PF-08065010 is an investigational small molecule drug being developed by Pfizer, Inc. It is currently in Phase 1 clinical development, with one active trial studying how different amounts of the study medicine are tolerated and act in the body of healthy adults. No approved indication has been announced.
PF-08065010 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the Phase 1 study evaluating the compound in healthy adult volunteers.
PF-08065010 is in Phase 1 clinical development. It is investigational and has not been approved for any indication. One Phase 1 trial is currently recruiting, and no trials for this compound have been completed.
PF-08065010 is being studied in one Phase 1 trial, NCT07235163, titled a study to learn how different amounts of the study medicine called PF-08065010 are tolerated and act in the body of healthy adults. The trial is recruiting, is randomized, double-blind, and controlled, and plans to enroll 100 participants in Belgium.
The Phase 1 trial NCT07235163 is enrolling healthy adult volunteers of all sexes who are 18 years of age or older. It is a randomized, double-blind, controlled study of 100 participants being conducted in Belgium, and it is currently recruiting.